GS
LIMNW

GTS Securities’s Liminatus Pharma Warrants LIMNW Stock Holding History

GTS Securities’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.57K Sell
20,929
-100
-0.5% -$7 ﹤0.01% 1308
2026
Q1 		$841 Sell
21,029
-8,671
-29% -$555 ﹤0.01% 1470
2025
Q4 		$1.04K Sell
29,700
-300
-1% -$30 ﹤0.01% 1345
2025
Q3 		$4.44K Buy
+30,000
New +$5.86K ﹤0.01% 1396

Other funds holding LIMNW

AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

GTS Securities's LIMNW Position: Q2 2026 in Review

GTS Securities reduced its Liminatus Pharma Warrants (LIMNW) stake by 0.48% in Q2 2026, selling an estimated $7 and leaving 20,929 shares worth $1.57K. The position accounts for ﹤0.01% of the portfolio, ranked #1308.

GTS Securities first reported a position in LIMNW in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.44K in Q3 2025. 22 funds tracked by Wall St. Rank hold LIMNW as of Q2 2026.

  • GTS Securities held 20,929 shares of Liminatus Pharma Warrants worth $1.57K as of Q2 2026.
  • GTS Securities sold 100 Liminatus Pharma Warrants shares in Q2 2026, an estimated $7.
  • Liminatus Pharma Warrants made up ﹤0.01% of GTS Securities's portfolio in Q2 2026, its #1308 holding.
  • GTS Securities first reported a position in Liminatus Pharma Warrants in Q3 2025 and has held it in 4 quarters since.
  • GTS Securities's Liminatus Pharma Warrants position peaked at $4.44K in Q3 2025.
  • 22 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.